Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Digital solutions provider Cambridge Cognition said it had won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1m.
The first of these larger trials leveraged the company's digital health capabilities in a new clinical field for the company. The second was a phase two study investigating the cognitive impact of a new drug for a neurodegenerative disorder.
'There is a great interest being shown in moving to virtual trials and we expect this to be a fast growth segment of the market for years to come, even once the COVID-19 crisis has eased,' the company said.
At 10:03am: (LON:COG) Cambridge Cognition Holdings share price was +3p at 27.5p